Neutralizing interleukin-13 increases skin microbial diversity: results from a Phase 3, randomized, double-blind, placebo-controlled trial of tralokinumab in adult patients with atopic dermatitis

Main Article Content

Thomas Bieber
Lisa Beck
Andrew Pink
Hidehisa Saeki
Lawrence Eichenfeld
Thomas Werfel
Anders Rosholm
Mads Ropke
Amy Paller

Keywords

IL-13, tralokinumab, atopic dermatits, skin microbiome

Abstract

N/A

References

1. Ogonowska P et al. Front. Microbiol. 2021; 11:567090;

2. Wollenberg A et al. Br J Dermatol. 2020 Sep 30. doi: 10.1111/bjd.19574. Online ahead of print;

3. Silverberg et al. Br J Dermatol. 2020 Sep 30. doi: 10.1111/bjd.1957 3. Online ahead of print;

4. Guttman-Yassky E, etal. Poster presentation at AAD VMX 2021;

5. Guttman-Yassky E, et al. Late-breaking presentation at AAD VMX 2021.

Most read articles by the same author(s)

1 2 3 > >>